For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib.The adverse reaction was milder in gefitinib group than that of erlotinib group.And with Guangzhou medical insurance, gefitinib had a superior cost-effectiveness ratio. Here, EGFR is linked to non-small cell lung carcinoma.